{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:18:51Z","timestamp":1785903531152,"version":"3.56.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R21 CA256644"],"award-info":[{"award-number":["R21 CA256644"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009730","name":"EIF | Stand Up To Cancer","doi-asserted-by":"publisher","award":["SU2C\u2010AACR\u2010DT\u201028\u201018"],"award-info":[{"award-number":["SU2C\u2010AACR\u2010DT\u201028\u201018"]}],"id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-024-01161-0","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T11:01:37Z","timestamp":1728903697000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Patient preferences for intervention in the setting of precursor multiple myeloma"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9128-3012","authenticated-orcid":false,"given":"Catherine R.","family":"Marinac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8782-4971","authenticated-orcid":false,"given":"Katelyn","family":"Downey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Fisher-Longden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4799-1900","authenticated-orcid":false,"given":"Timothy R.","family":"Rebbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8419-1091","authenticated-orcid":false,"given":"Urvi A.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth K.","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7361-3092","authenticated-orcid":false,"given":"Irene M.","family":"Ghobrial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Nadeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Egleston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"key":"1161_CR1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa1709974","volume":"378","author":"RA Kyle","year":"2018","unstructured":"Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, et al. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. N Engl J Med. 2018;378:241\u20139.","journal-title":"N Engl J Med"},{"key":"1161_CR2","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1182\/asheducation-2013.1.478","volume":"2013","author":"O Landgren","year":"2013","unstructured":"Landgren O. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies. Hematol Am Soc Hematol Educ Program. 2013;2013:478\u201387.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"1161_CR3","first-page":"578","volume":"25","author":"RA Kyle","year":"2011","unstructured":"Kyle RA, Rajkumar SV. Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Oncology (Williston Park). 2011;25:578\u201386.","journal-title":"Oncology (Williston Park)"},{"key":"1161_CR4","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1182\/blood-2014-08-551549","volume":"124","author":"IM Ghobrial","year":"2014","unstructured":"Ghobrial IM, Landgren O. How I treat smoldering multiple myeloma. Blood. 2014;124:3380\u20138.","journal-title":"Blood"},{"key":"1161_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2021.101901","volume":"51","author":"B Murphy","year":"2021","unstructured":"Murphy B, McShane CM, Santin O, Treanor C, Byrne B, Donnelly M, et al. Patient\u2019s perspectives of living with a precancerous condition: Monoclonal gammopathy of undetermined significance (MGUS). Eur J Oncol Nurs. 2021;51:101901.","journal-title":"Eur J Oncol Nurs"},{"key":"1161_CR6","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa1300439","volume":"369","author":"MV Mateos","year":"2013","unstructured":"Mateos MV, Hernandez MT, Giraldo P, de la Rubia J, de Arriba F, Lopez Corral L, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N. Engl J Med. 2013;369:438\u201347.","journal-title":"N. Engl J Med"},{"key":"1161_CR7","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1200\/JCO.19.01740","volume":"38","author":"S Lonial","year":"2020","unstructured":"Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ. et al. Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. J Clin Oncol. 2020;38:1126\u201337.","journal-title":"J Clin Oncol"},{"key":"1161_CR8","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","volume":"1","author":"N Korde","year":"2015","unstructured":"Korde N, Roschewski M, Zingone A, Kwok M, Manasanch EE, Bhutani M, et al. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. JAMA Oncol. 2015;1:746\u201354.","journal-title":"JAMA Oncol"},{"key":"1161_CR9","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1001\/jamaoncol.2021.3971","volume":"7","author":"D Kazandjian","year":"2021","unstructured":"Kazandjian D, Hill E, Dew A, Morrison C, Roswarski J, Korde N, et al. Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial. JAMA Oncol. 2021;7:1678\u201385.","journal-title":"JAMA Oncol"},{"key":"1161_CR10","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1182\/blood.2021011670","volume":"140","author":"I Vaxman","year":"2022","unstructured":"Vaxman I, Gertz MA. How I approach smoldering multiple myeloma. Blood. 2022;140:828\u201338.","journal-title":"Blood"},{"key":"1161_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102272","volume":"65","author":"GR Mohyuddin","year":"2023","unstructured":"Mohyuddin GR, Chakraborty R, Cliff ERS, Derman BA. Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey. EClinicalMed. 2023;65:102272.","journal-title":"EClinicalMed"},{"key":"1161_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40271-022-00589-5","volume":"16","author":"H Gelhorn","year":"2023","unstructured":"Gelhorn H, Ross MM, Kansal AR, Fung ET, Seiden MV, Krucien N, et al. Patient Preferences for Multi-Cancer Early Detection (MCED) Screening Tests. Patient. 2023;16:43\u201356.","journal-title":"Patient"},{"key":"1161_CR13","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1136\/bmj.320.7248.1530","volume":"320","author":"M Ryan","year":"2000","unstructured":"Ryan M, Farrar S. Using conjoint analysis to elicit preferences for health care. Brit Med J. 2000;320:1530\u20133.","journal-title":"Brit Med J"},{"key":"1161_CR14","doi-asserted-by":"publisher","first-page":"e1634","DOI":"10.1212\/WNL.0000000000007245","volume":"92","author":"RJ Fox","year":"2019","unstructured":"Fox RJ, Cosenza C, Cripps L, Ford P, Mercer M, Natarajan S, et al. A survey of risk tolerance to multiple sclerosis therapies. Neurology. 2019;92:e1634\u2013e42.","journal-title":"Neurology"},{"key":"1161_CR15","doi-asserted-by":"publisher","first-page":"dju139","DOI":"10.1093\/jnci\/dju139","volume":"106","author":"J Peres","year":"2014","unstructured":"Peres J. Why is breast cancer chemoprevention such a hard sell? J Natl Cancer Inst. 2014;106:dju139","journal-title":"J Natl Cancer Inst"}],"updated-by":[{"DOI":"10.1038\/s41408-024-01174-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000}}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01161-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01161-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01161-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T04:04:26Z","timestamp":1729569866000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01161-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1161"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01161-0","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41408-024-01174-9","asserted-by":"object"}]},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,14]]},"assertion":[{"value":"28 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41408-024-01174-9","URL":"https:\/\/doi.org\/10.1038\/s41408-024-01174-9","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Ghobrial has served as a consultant for AbbVie, Adaptive, Aptitude Health, BMS, Cellectar, CurioScience, Genetch, Janssen, Janssen Central American and Caribbean, Karyopharm, Medscape, Oncopeptides, Sanofi, Takeda, The Binding Site, Gene Network Sciences Healthcare, and GSK. Dr Ghobrial\u2019s spouse, William Savage, is CMO and equity holder at Disc Medicine. All other authors declare no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"175"}}